WO2016158883A1 - Produit cosmétique contenant un hydrogel - Google Patents

Produit cosmétique contenant un hydrogel Download PDF

Info

Publication number
WO2016158883A1
WO2016158883A1 PCT/JP2016/059983 JP2016059983W WO2016158883A1 WO 2016158883 A1 WO2016158883 A1 WO 2016158883A1 JP 2016059983 W JP2016059983 W JP 2016059983W WO 2016158883 A1 WO2016158883 A1 WO 2016158883A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin cosmetic
skin
hydrogel
water
acid
Prior art date
Application number
PCT/JP2016/059983
Other languages
English (en)
Japanese (ja)
Inventor
美次 佐藤
Original Assignee
株式会社キレートジャパン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社キレートジャパン filed Critical 株式会社キレートジャパン
Priority to CN201680016786.3A priority Critical patent/CN107405279A/zh
Publication of WO2016158883A1 publication Critical patent/WO2016158883A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a skin cosmetic that has high permeability to skin, high stability of active ingredients, and long-lasting effects.
  • Patent Documents 1 and 2 As an application example of a hydrogel related to the cosmetic field, a hair growth hydrogel impregnated with a cell growth factor protein so as to be sustained-released has been proposed (Patent Document 3).
  • This hair-restoring hydrogel is mainly implanted subcutaneously or injected subcutaneously or into blood vessels.
  • the present inventors examined the application of hydrogel to skin cosmetics for the purpose of sustained release of skin cosmetic ingredients.
  • the hydrogel was directly blended into cosmetics to enhance the sustained release, the permeability to the skin did not reach a satisfactory level.
  • the temporal stability of components such as cell growth factors in an aqueous medium is low, and it has not been possible to obtain a product that is satisfactory as a product in cosmetics that require long-term stability.
  • the present inventors have studied various developments of unprecedented cosmetics that maintain the stability of active ingredients, have high permeability to the skin, and are expected to have a sustained release effect.
  • encapsulating the hydrogel in the liposome together with the active ingredient synergistically increases the permeability to the skin, and freeze-drying it is expected to dramatically increase the stability over time.
  • the inventors have found that an external effect can be obtained and completed the present invention.
  • the present invention provides the following (1) to (10).
  • a skin cosmetic comprising a hydrogel carrying a skin cosmetic component and a liposome-constituting lipid.
  • the skin cosmetic according to any one of the above (1) to (4), wherein the liposome-constituting lipid is a synthetic lipid containing a PEG chain.
  • kits for skin cosmetic preparation which provides the freeze-dried skin cosmetic according to (6) above and water for dissolving it in separate containers.
  • (10) A group in which water for dissolution is composed of hyaluronic acid, collagen, amino acids, vitamins, placenta extract, ceramide, arbutin, retinol, elastin, ellagic acid, hydroquinone, tranexamic acid, kojic acid, and pyrroloquinoline quinone (PQQ)
  • the kit according to (9) above which is an aqueous solution in which a further active ingredient selected from is dissolved.
  • the present invention provides a skin cosmetic that has high permeability to the skin, high stability of active ingredients, and long-lasting effects.
  • the cosmetic of the present invention can be an aqueous cosmetic or an oil-in-water cosmetic.
  • the cosmetic of the present invention is a freeze-dried cosmetic that can be redissolved and redispersed by the addition of water or an aqueous solution.
  • the skin cosmetic of the present invention includes a hydrogel carrying a skin cosmetic component and a liposome-constituting lipid.
  • the “skin cosmetic component” may be any as long as it is used in the cosmetic field, and is not particularly limited.
  • various growth factors include animal-derived components such as (human adipocyte conditioned culture fluid extract), plant-derived components such as vitamins and plant extracts, and various peptides.
  • the growth factor include epidermal growth factor (Epidermal Growth Factor, EGF), fibroblast growth factor (FiFGF), keratinocyte growth factor (Keratinocyte Growth Factor, KGF), and the like.
  • the skin cosmetic ingredient to be blended in the skin cosmetic of the present invention is not particularly limited, but it is desired to be blended into the cosmetic because it can exert the effects of the present invention, but is stable in water. It is preferable to include a component that has been difficult to formulate because of its low content, such as a growth factor.
  • “Hydrogel” is a general term for polymer compounds containing water and having a network structure (crosslinked structure), and a constituent polymer and water contained therein are constituent components.
  • Hydrogels have a three-dimensional network of hydrophilic polymers formed by a crosslinked structure so that a large amount of water can be absorbed and retained.
  • the hydrogel is roughly classified into chemical crosslinked gel and physical crosslinked gel depending on the type of crosslinked structure. Is done.
  • acrylic acid, acrylamide, N-vinyl pyrrolidone, 2-hydroxyethyl methacrylate and the like are used as the hydrophilic monomer constituting the chemical cross-linking gel, and N, N'- Examples include methylene bisacrylamide and ethylene glycol dimethacrylate, and a hydrogel can be synthesized by appropriately polymerizing these. It is also possible to synthesize a hydrogel by crosslinking a linear polymer.
  • a polymer such as polyvinyl alcohol or a cellulose derivative can be reacted with a bifunctional crosslinking agent.
  • a bifunctional crosslinking agent such as polyvinyl alcohol or a cellulose derivative
  • it is also known to physically crosslink synthetic polymers such as polyvinyl alcohol and polyethylene glycol, or natural polymers such as alginic acid, pectin, hyaluronic acid and gelatin under specific conditions.
  • gelatin hydrogel obtained by crosslinking gelatin or gelatin derivatives as medical hydrogel can be suitably used as a drug delivery system in regenerative medicine (International Publication No. 2006/085653 and International Publication No. 2008/016163).
  • these various gelatin hydrogels can be suitably used.
  • hydrogels can be used.
  • Medgel® PI5, Medgel® PI9, Medgel SP®PI5, Medgel® SP®PI9, Medgel® E50 manufactured by Wako Pure Chemical Industries, Ltd.
  • a hydrogel having a molecular weight of 30,000 or less is preferable to use.
  • the hydrogel is in the form of an aqueous solution before lyophilization and at the time of use, and its concentration in the cosmetic at the time of use is generally in the range of 0.1 to 10% by weight, preferably 2 to 5% by weight.
  • ⁇ At least one skin cosmetic ingredient is supported on hydrogel. Since the hydrogel can be obtained in a dry state in the above-mentioned commercial products, when an aqueous solution containing a skin cosmetic component is gradually added to the hydrogel, the skin cosmetic component is stably incorporated into the gelatin network structure. Retained. Moreover, even if it is the original form of hydrogel containing water, retention of the skin cosmetic component in a hydrogel is achieved by mixing with the aqueous solution containing a skin cosmetic component.
  • the amount of the skin cosmetic component carried in the hydrogel is not particularly limited, but the hydrogel amount may be in the range of 10 to 500 times the dry skin weight of the skin cosmetic component. Is preferred.
  • the present inventors also examined the use of liposomes in order to improve the permeability and sustained release properties of skin cosmetic ingredients. That is, in the present invention, the hydrogel carrying the skin cosmetic component is preferably in a form encapsulated in liposomes.
  • Liposome is an artificial closed vesicle of a lipid bilayer membrane originally formed from a phospholipid that is a constituent of a biological membrane, and was first reported by Bangham et al. In 1965.
  • Phospholipid molecules are amphipathic lipids consisting of a hydrophilic group and a hydrophobic group, forming a vesicle consisting of one or more lipid bilayers in which the molecules are aligned with the hydrophobic part on the inside and the hydrophilic part on the outside. To do. Utilizing such properties, it is known that liposomes can be used as capsules that contain a water-soluble substance and can contain a fat-soluble substance in a hydrophobic part, and are also used in cosmetics. As the liposome, monolayer liposomes and multilayer liposomes can be obtained by the production method, and natural phospholipids having a wide range of diameters from 40 nm to 1000 nm can be obtained.
  • the skin cosmetic of the present invention can remarkably improve the permeability of the skin cosmetic component into the skin by encapsulating the hydrogel carrying the skin cosmetic component in the liposome.
  • Liposomes that can be used in the skin cosmetics of the present invention are composed of natural or synthetic phospholipids, such as phospholipids derived from egg yolk, soybeans, cereals, etc., and hydrogenation of these natural phospholipids Treated phospholipids and the like can be used as appropriate.
  • Known phospholipids constituting the liposome include phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidic acid, and the like.
  • sterols such as cholesterol and components such as glycolipids can be included for the purpose of improving the stability of the liposome.
  • liposomes using synthetic lipids having a polyethylene glycol (PEG) chain are proposed.
  • PEGylated diacylglycerol in which PEG is bonded to the OH group of diacylglycerol can be suitably used.
  • PEG-12 glyceryl dioleate (PEG-12 GDO) PEG- 12 glyceryl dimyristate (PEG-12 GDM)
  • PEG-12 glyceryl distearate PEG-12 GDS
  • PEG-23 glyceryl dipalmitate PEG-23 GDP
  • PEG-23 glyceryl distearate PEG- 23 GDS.
  • All of these lipids can spontaneously form liposomes at the melting point, and do not require complicated steps as in the case of using natural phospholipids.
  • the use of PEG-12 GDO, PEG-12 GDM, and PEG-23 GDP is more preferred, and the use of PEG-12 GDO and PEG-12 GDM is even more preferred. Since PEG-12 GDO and PEG-12 GDM can spontaneously form liposomes even at room temperature, they are particularly suitable in the embodiment of the present invention in which a user reconstitutes a freeze-dried state.
  • those skilled in the art can use the above lipids alone or in other ways, taking into account, for example, the balance between the hydrophilic and hydrophobic groups of the constituent lipids, for example packing parameters that can be a measure of the ease of liposome formation. It can be used as a liposome-constituting lipid in combination with other lipids.
  • the lipid having the above structure may be synthesized, and can be obtained as a commercial product from, for example, NOF Corporation.
  • liposome formation can be achieved by simply mixing the PEGylated diacylglycerol with water or an aqueous solution and optionally heating to the melting point (transition temperature) of the constituent lipids. it can.
  • the hydrogel is allowed to coexist, a liposome encapsulating the hydrogel is formed.
  • the blending ratio of the hydrogel and the lipid constituting the liposome is preferably in the range of 20:80 to 80:20 on the basis of the dry weight, although it depends on the concentration and particle size of the hydrogel.
  • the particle size of the liposomes in the reconstituted aqueous cosmetic is relatively stable within the range of 75 to 150 nm.
  • the encapsulation rate of the hydrogel in the liposome may vary depending on the amount of water or aqueous solution to be added, it is preferably 20% or more, preferably 50% or more, more preferably 80% or more.
  • the skin cosmetic of the present invention can also be supplied in lyophilized form until use.
  • Freeze-drying is a technology used in the food, pharmaceutical, and cosmetic fields, and is not particularly limited.
  • cosmetics such as serums are not a single ingredient like foods and pharmaceuticals. Since a plurality of components are blended and the aesthetic appearance before restoration is required to be excellent, it is necessary to carefully determine lyophilization conditions.
  • lyophilization is performed at about -85 ° C to -30 ° C, preferably -85 ° C to -85 ° C, so as not to form large ice crystals, for example. It is preferably carried out at a temperature in the range of 50 ° C., preferably under a vacuum condition of 3 to 20 Pa, more preferably 3 to 5 Pa.
  • Freeze-dried products can be stored at room temperature, and are suitable for long-term storage of components with low stability in aqueous solutions.
  • this step can provide the skin cosmetic of the present invention to the consumer in a lyophilized state, and the consumer who purchased the product himself can re-dissolve (reconstitute) at his convenience.
  • re-dissolving in water it is preferably stored in a cool place such as a refrigerator and used up in about 10 days to 2 weeks. These are described in the instruction manual attached to the product.
  • the water used for dissolution can be tap water or water filtered with a water purifier in consideration of the fact that consumers themselves dissolve. Moreover, it can also be set as the aqueous solution in which the further active ingredient is contained in the water for melt
  • the hydrogel-containing cosmetic in a lyophilized form and water for dissolving the same can be placed in separate containers and provided as a kit for preparing the skin cosmetic at the time of use.
  • Further active ingredients may be any ingredients that are usually blended in cosmetics and are stable in water, such as hyaluronic acid, collagen, amino acids, vitamins, placenta extract, ceramide, arbutin, retinol, elastin, ellagic acid, Examples include those selected from the group consisting of hydroquinone, tranexamic acid, kojic acid, and pyrroloquinoline quinone (PQQ), which can be incorporated into a lyophilized hydrogel.
  • hyaluronic acid collagen
  • amino acids amino acids
  • vitamins placenta extract
  • ceramide arbutin
  • retinol retinol
  • elastin ellagic acid
  • examples include those selected from the group consisting of hydroquinone, tranexamic acid, kojic acid, and pyrroloquinoline quinone (PQQ), which can be incorporated into a lyophilized hydrogel.
  • PQQ pyrroloquinoline quin
  • the cosmetic of the present invention can be in the form of lotion, milky lotion, cream or the like, but is particularly preferably in the form of a cosmetic liquid used by the user by redissolving in water immediately before use.
  • EGF rh-OLIGOPEPTIDE-1 (2 ⁇ g / mL)
  • EGF rh-OLIGOPEPTIDE-1 + Cross-linked gelatin (10%)
  • EGF rh-OLIGOPEPTIDE-1 + Nanosome encapsulation agent
  • PEG-12 GDM Nanosome encapsulation agent
  • test substance 0.1 mL was added to the side. Two hours later, the total amount of the permeate in the assay tray was collected and subjected to EGF quantitative test using an ELISA kit (EGF Human ELISA Kit, R & D Systems, Cat. #: DEG00). The operation followed the instructions included with the kit.
  • Table 1 shows the transmission magnification of the treatment group when the transmittance in the treatment group (1) is 1.
  • the permeability of EGF to the artificial skin increased to about 30 times that of EGF alone even when gelatin hydrogel was added. When nanosomes were formed, the increase was about 125 times. When mixed with gelatin hydrogel and further encapsulated in nanosomes, the permeability increased about 421 times.
  • Example 2 Confirmation of stabilization effect by freeze-drying It was confirmed that freeze-drying treatment improved the temporal stability of EGF (rh-OLIGOPEPTIDE-1) and FGF (rh-OLIGOPEPTIDE-11).
  • EGF and FGF were each prepared in phosphate buffered saline (PBS) at a concentration of 100 mg / mL, and lyophilized or at room temperature in an aqueous solution without lyophilization. The remaining amount was stored and measured. Residual activity was evaluated by the MTS method of Hela cells (using Cell Titer96 (registered trademark) Aqueous One Solution Cell Proliferation Assay (Promega)). The results are shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un produit cosmétique de peau qui présente une grande perméabilité à la peau, présente une stabilité élevée d'un principe actif et exerce un effet de longue durée. Le produit cosmétique de peau fourni par la présente invention contient un hydrogel qui porte un ingrédient cosmétique de peau et un lipide constituant un liposome. Le produit cosmétique de peau selon la présente invention est de préférence fourni dans un état lyophilisé. Selon la présente invention, un élément, qui a une faible stabilité et ne pouvait donc pas être utilisé en cosmétique jusqu'à présent, devient utilisable et des propriétés de perméabilité de peau et de libération prolongée de ce dernier peuvent être obtenues. En conséquence, un produit cosmétique hautement efficace qui est utile pour des consommateurs peut être fourni.
PCT/JP2016/059983 2015-03-27 2016-03-28 Produit cosmétique contenant un hydrogel WO2016158883A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680016786.3A CN107405279A (zh) 2015-03-27 2016-03-28 含有水凝胶的化妆品

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-067361 2015-03-27
JP2015067361A JP6522387B2 (ja) 2015-03-27 2015-03-27 ハイドロゲル含有化粧料

Publications (1)

Publication Number Publication Date
WO2016158883A1 true WO2016158883A1 (fr) 2016-10-06

Family

ID=57004266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/059983 WO2016158883A1 (fr) 2015-03-27 2016-03-28 Produit cosmétique contenant un hydrogel

Country Status (3)

Country Link
JP (1) JP6522387B2 (fr)
CN (1) CN107405279A (fr)
WO (1) WO2016158883A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3473236B1 (fr) * 2017-10-17 2021-04-28 LvmH Recherche Microgels pour administration de substances organiques actives cosmétiques
CN110354003B (zh) * 2019-07-08 2022-05-27 广州贝研生物科技有限公司 传明酸作为冻干粉赋形剂的应用及冻干工艺
JP6805385B1 (ja) * 2020-08-31 2020-12-23 ジェイ−ネットワーク，インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
WO2022225046A1 (fr) * 2021-04-23 2022-10-27 ミヨシ油脂株式会社 Composition propice à la formation de gel ou aux caractéristiques d'épaississement
KR102628359B1 (ko) * 2023-10-12 2024-01-24 주식회사 마이센 스몰 리포좀 액정 유화 화장료 조성물, 및 이를 포함하는 미백, 주름 개선 및 보습용 다기능성 화장품

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02111799A (ja) * 1988-10-20 1990-04-24 Denki Kagaku Kogyo Kk コロニー刺激因子を含有するゼラチンマイクロスフェアー
JPH06505913A (ja) * 1990-11-21 1994-07-07 ヤン，クイン ゲルビーズ及び同様な材料においてリポソームを固定化する方法，このような方法によって調製された固定化リポソーム，及びそれらの使用
JP2003508127A (ja) * 1999-08-27 2003-03-04 デパートメント オブ ナショナル ディフェンス リポソームで被包された治療薬を含むヒドロゲル傷被覆用品
JP2007224012A (ja) * 2006-01-30 2007-09-06 Fujifilm Corp 酵素架橋したタンパク質ナノ粒子
JP2008133195A (ja) * 2006-11-27 2008-06-12 Konica Minolta Holdings Inc 水溶性薬剤内包リポソーム及びその製造方法
JP2009510168A (ja) * 2005-10-03 2009-03-12 マーク エー． ピンスカイ 改善されたスキンケアのための組成物および方法
KR20090037723A (ko) * 2007-10-12 2009-04-16 세원셀론텍(주) 아텔로콜라겐을 포집한 리포좀과 그 제조방법 및 사용방법
JP2009249370A (ja) * 2008-04-11 2009-10-29 Fujifilm Corp タンパク質ナノ粒子
JP2010501197A (ja) * 2006-08-31 2010-01-21 ネステク ソシエテ アノニム 食品タンパク質と荷電した乳化剤との相互作用
WO2013155487A1 (fr) * 2012-04-12 2013-10-17 Yale University Véhicules pour l'administration contrôlée de différents agents pharmaceutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160582A (zh) * 1996-12-27 1997-10-01 暨南大学生物工程研究所 含有细胞生长因子的皮肤外用组合物
CN1163218C (zh) * 1999-09-10 2004-08-25 广州市华桑生物工程有限公司 新型护肤化妆品
DE10042576B4 (de) * 2000-08-15 2004-08-12 Coty B.V. Kosmetischer Basiskomplex und dessen Verwendung
JP2009191004A (ja) * 2008-02-14 2009-08-27 Pars Co Ltd 成長因子を含有するリポソームを含む皮膚外用剤及びその製造方法
JP2011526623A (ja) * 2008-06-30 2011-10-13 オーアールエフ・リフタエクニ・エイチエフ スキンケアにおける植物由来の組み換え増殖因子の使用
JP5757563B2 (ja) * 2011-05-13 2015-07-29 株式会社ツツミプランニング 化粧料

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02111799A (ja) * 1988-10-20 1990-04-24 Denki Kagaku Kogyo Kk コロニー刺激因子を含有するゼラチンマイクロスフェアー
JPH06505913A (ja) * 1990-11-21 1994-07-07 ヤン，クイン ゲルビーズ及び同様な材料においてリポソームを固定化する方法，このような方法によって調製された固定化リポソーム，及びそれらの使用
JP2003508127A (ja) * 1999-08-27 2003-03-04 デパートメント オブ ナショナル ディフェンス リポソームで被包された治療薬を含むヒドロゲル傷被覆用品
JP2009510168A (ja) * 2005-10-03 2009-03-12 マーク エー． ピンスカイ 改善されたスキンケアのための組成物および方法
JP2007224012A (ja) * 2006-01-30 2007-09-06 Fujifilm Corp 酵素架橋したタンパク質ナノ粒子
JP2010501197A (ja) * 2006-08-31 2010-01-21 ネステク ソシエテ アノニム 食品タンパク質と荷電した乳化剤との相互作用
JP2008133195A (ja) * 2006-11-27 2008-06-12 Konica Minolta Holdings Inc 水溶性薬剤内包リポソーム及びその製造方法
KR20090037723A (ko) * 2007-10-12 2009-04-16 세원셀론텍(주) 아텔로콜라겐을 포집한 리포좀과 그 제조방법 및 사용방법
JP2009249370A (ja) * 2008-04-11 2009-10-29 Fujifilm Corp タンパク質ナノ粒子
WO2013155487A1 (fr) * 2012-04-12 2013-10-17 Yale University Véhicules pour l'administration contrôlée de différents agents pharmaceutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERGEY KAZAKOV: "Lipobeads as Future Drug Delivery System", NANOTECHNOLOGY IN DRUG DELIVERY, pages 85 - 129, XP055315710, Retrieved from the Internet <URL:http://www.onecentralpress.com/wp-content/uploads/2016/02/NDD-4-Chapter-4-NEW.pdf> *

Also Published As

Publication number Publication date
CN107405279A (zh) 2017-11-28
JP6522387B2 (ja) 2019-05-29
JP2016185933A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
WO2016158883A1 (fr) Produit cosmétique contenant un hydrogel
Tan et al. Biopolymer-liposome hybrid systems for controlled delivery of bioactive compounds: Recent advances
Boge et al. Cubosomes for topical delivery of the antimicrobial peptide LL-37
Maherani et al. Liposomes: a review of manufacturing techniques and targeting strategies
JP4758915B2 (ja) 多重層リポソームおよびその製造方法
ES2754523T3 (es) Composiciones estimulantes de células madre
CN111544317B (zh) 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用
Guo et al. Preparation of PEG-modified proanthocyanidin liposome and its application in cosmetics
US20220133604A1 (en) Multi-coated nanoparticles comprising multiple coating layers of chitosan and polyglutamic acid, composition for skin care comprising the same and method for manufacturing the same
US7824708B2 (en) Liposome containing cardiolipin for improvement of mitochondrial function
Chun et al. Production of low molecular collagen peptides-loaded liposomes using different charged lipids
Maurya et al. Enhanced transdermal delivery of indinavir sulfate via transfersomes
WO2023237004A1 (fr) Composition de lyophilisation ternaire et son utilisation dans une formulation lyophilisée
KR102281703B1 (ko) 카티온화 베시클 및 그 조성물
US5776470A (en) Method of using lipid transfer proteins and lipids to reconstitute membranes
JP5916743B2 (ja) ヘモグロビン含有リポソーム及びその製法
JP2678138B2 (ja) 牛乳を含むｏ／ｗ型エマルジョン化粧料組成物
KR20160091315A (ko) 다제내성 그램 양성균 항균제 및 외용제
CN102552149A (zh) 一种注射用肝素钙脂质体制剂
Tansathien et al. Investigation of lipid nanocarriers and microspicule gel for dermal delivery of porcine placenta extract
CN110384625A (zh) 一种仿生胎脂的脂质体组合物、其制备方法和应用
Wang et al. Lecithin/cholesterol/tween 80 liposomes for Co-encapsulation of vitamin C and xanthoxylin
Sapkota Liposomes and Transfersomes for the Topical Delivery of Papain in the Treatment of Hypertrophic Scars
Pettersen Liposomal formulations for membrane active antimicrobials–Assuring safety through an optimised drug delivery system
Basto Optimization of topical delivery for niacinamide using hydrogels and transethosomes for anti-ageing effect

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16772764

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16772764

Country of ref document: EP

Kind code of ref document: A1